BCM
ALNY icon

Bronte Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bronte Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Sell
35,384
-1,861
-5% -$561K 1.14% 21
2026
Q1 		$12.3M Sell
37,245
-1,619
-4% -$551K 1.22% 20
2025
Q4 		$15.5M Buy
38,864
+3,890
+11% +$1.72M 1.54% 13
2025
Q3 		$17.8M Buy
+34,974
New +$14.2M 1.6% 15

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bronte Capital Management's ALNY Position: Q2 2026 in Review

Bronte Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 5% in Q2 2026, selling an estimated $561K and leaving 35,384 shares worth $10.7M. The position accounts for 1.14% of the portfolio, ranked #21.

Bronte Capital Management first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $17.8M in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Bronte Capital Management held 35,384 shares of Alnylam Pharmaceuticals worth $10.7M as of Q2 2026.
  • Bronte Capital Management sold 1,861 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $561K.
  • Alnylam Pharmaceuticals made up 1.14% of Bronte Capital Management's portfolio in Q2 2026, its #21 holding.
  • Bronte Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Bronte Capital Management's Alnylam Pharmaceuticals position peaked at $17.8M in Q3 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.